Business Wire

MA-VERACODE

22.9.2022 14:32:58 CEST | Business Wire | Press release

Share
Healthcare Sector Leads the Way for Fix Rate of Software Security Flaws

Veracode, a leading global provider of application security testing solutions, today revealed that the healthcare sector takes first place for the proportion of software security flaws that are fixed, at 27 percent. The sector overtook financial services as the top-performing industry, demonstrating healthcare providers have made good headway toward the goal of making their software more secure over the past year.

The data was published in the company’s annual State of Software Security (SoSS) report v12, which analyzed 20 million scans across half a million applications in the healthcare, financial, technology, manufacturing, retail, and government sectors.

Chris Eng, Chief Research Officer at Veracode, said, “Healthcare is one of the more highly regulated sectors and is considered critical infrastructure by the government, so it’s encouraging to see the sector performs comparatively well in terms of overall flaw remediation. We hope healthcare developers and IT staff see this as a welcome ray of sunshine amidst the all-too-often gloomy realm of software security. There is still work to do, so here’s to more improvements in the years to come.”

Despite taking the top spot for fix rate, 77 percent of applications in the healthcare industry contain vulnerabilities, with 21 percent of applications containing high severity vulnerabilities. The sector also has ample room for improvement in terms of the time spent to fix flaws once they’re detected, taking up to a whopping 447 days to reach the halfway point of remediation.

Healthcare Breach Costs Are the Most Expensive

With healthcare companies incurring the highest average breach costs, at a new record high of $10.1 million*, taking proactive steps to minimize the risk of a cyberattack is imperative. Since data breaches in highly regulated industries tend to be associated with larger long-term costs that accrue over the ensuing years, the industry would benefit from even greater comprehensive efforts to address security earlier in the software development lifecycle.

Of the six industries analyzed, healthcare providers rank toward the bottom for the proportion of applications with any flaws, and second to last for the percentage of high-severity flaws—defined as those that present a serious risk to the application and organization if they were to be exploited. When it comes to the types of flaws discovered from dynamic analysis of applications in the sector, compared to other industries healthcare providers perform well for authentication issues and insecure dependencies, but have a higher incidence of cryptographic and deployment configuration issues.

Eng said, “We know that no application will ever be 100 percent free of security flaws, so it’s important that businesses take all necessary steps to minimize risk as much as possible. This includes scanning at a regular, rapid pace using multiple testing types, integrating testing tools into developer environments, and providing hands-on training to help developers understand the origin of flaws and how to fix or prevent them entirely. The healthcare sector should also take extra care to prioritize critical flaws—those vulnerabilities that could have a catastrophic impact if left unaddressed for too long.”

Andrew McCall, Vice President of Engineering, Azalea Health Innovations, said, “The biggest obstacle to building security into our workflows is that developers will treat security as just a checkbox. But security is an ongoing process and has to be top of mind throughout the software development life cycle. We chose Veracode because it was the easiest and best solution when it comes to integrating into our existing processes.”

Third-party Library Security

Considering a sharp increase in regulations to secure the software supply chain over the past year, the report analyzed third-party libraries to identify how vulnerabilities discovered through software composition analysis (SCA) behave. Overall, around 30 percent of vulnerable libraries remain unresolved after two years; however, that statistic reduces to 25 percent for the healthcare sector. In fact, while the overall ratio of vulnerable libraries found by SCA trends down steadily over time, healthcare experienced a brief upward spike before driving rates down dramatically over the last year or so.

The Veracode State of Software Security v12 healthcare snapshot is available to download here and the full report is available here.

* IBM Security and The Ponemon Institute, “Cost of a Data Breach Report 2022”: https://www.ibm.com/downloads/cas/3R8N1DZJ, July 2022

About the State of Software Security Report

The Veracode State of Software Security (SoSS) v12 analyzed the full historical data from Veracode services and customers. This accounts for a total of more than half a million applications (592,720) that used all scan types, more than a million dynamic analysis scans (1,034,855), more than five million static analysis scans (5,137,882) and more than 18 million software composition analysis scans (18,473,203). All those scans produced 42 million raw static findings, 3.5 million raw dynamic findings, and six million raw SCA findings.

The data represents large and small companies, commercial software suppliers, software outsourcers, and open-source projects. In most analyses, an application was counted only once, even if it was submitted multiple times as vulnerabilities were remediated, and new versions uploaded.

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.

Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005100/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye